Major players in the specialty enzymes market are BASF SE, Novozymes A/S, Roche Holding AG, Codexis Inc. , Specialty Enzymes & Probiotics, Advanced Enzyme Technologies Ltd. , BBI Solutions, E. I. du Pont de Nemours and Company, Sanofi, and Amano Enzyme Inc.
New York, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Specialty Enzymes Global Market Report 2021: COVID-19 Implications And Growth To 2030" - https://www.reportlinker.com/p06151648/?utm_source=GNW
The global specialty enzymes market is expected to grow from $4.28 billion in 2020 to $4.41 billion in 2021 at a compound annual growth rate (CAGR) of 3%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $6.1 billion in 2025 at a CAGR of 8%.
The specialty enzymes market consists of sales of specialty enzymes which are proteins acting as biocatalysts to accelerate the rate of reactions.The revenue generated by the market involves the sales of specialty enzymes that include carbohydrases, proteases, lipasesand lipases, among others in liquid or dry form, which are produced either from microorganisms, plants or animals.
Specialty enzymes are primarily used in pharmaceutical, diagnostics, animal nutrition, food & beverage, research, and biotechnology.
The specialty enzymes market covered in this report is segmented by type into carbohydrases, proteases, lipases, polymerases & nucleases, oxidase & hydratases, others. It is also segmented by source into microorganisms, animals, plants and by application into pharmaceutical, diagnostics, research & biotechnology, food & beverage, animal nutrition, others.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Ethical and societal issues are factors that will slow down the market growth during the forecast period.The clashing public opinions on these issues will determine the acceptability of new industrial biotechnology products.
In 2019, a published article stated that there are five societal and ethical themes concerning industrial biotechnology namely sustainability, naturalness, risk management, innovation trajectories and economic justice.Many critics state the factor affecting economic justice is that the applications of industrial biotechnology lead to the concentration of knowledge and power in the hands of a few companies.
Thus, societal and ethical issues are expected to impact market growth.
In 2018, BRAIN AG, a Germany-based industrial biotechnology company that identifies and develops innovative solutions and products for use in chemistry, cosmetics and food industries, acquired a majority stake in Biocatalysts Ltd for an undisclosed amount.The acquisition will strengthen BRAIN’s BioIndustrial segment and widens commercial opportunities with Biocatalyst’s portfolio and technology including access to BRAIN’s unique BioArchive and Biocatalyst’s MetXtra metagenomic library.
Biocatalysts Ltd. is a UK-based manufacturer of specialty enzymes that focuses on the use of technology to develop novel specialty enzymes in a cost-effective manner.
Growing investment in biotechnology research & development is expected to boost market growth during the forecast period.Specialty enzymes are widely used in biotech research and development, particularly in molecular biology.
The increasing investment and an increase in the number of companies conducting biotechnology research & development will in turn increase the number of biotech researches. In 2018, the annual investment in UK biotechnology research & development was £2.2 billion which was up from the previous year (£1.2 billion) and there is a significant increase in the number of active companies involved in biotech research & development, which reached to 3,456 companies in 2018. There were 127 newer companies incorporated in just the first two months of 2019, which represents 3 new companies each new working day. Thus, the growing number of biotech research companies following increasing investments in biotech R&D is expected to boost the specialty enzymes market.
Technological advancements show opportunities for the production of enzyme products in a more efficient way.Challenges such as complexity in maintaining pH, operational high temperature of specialty enzymes and significant cost of maintenance of specialty enzyme products paves way for technological advancements.
In 2019, an article published in Plant Biotechnology Journal stated the commercial launch of leaf pectinase powder developed using a new platform technology namely leaf?production platform.The leaf pectinase powder produced using leaf-production platform showed promising results like functionality in broad pH/temperature ranges as crude leaf extracts, leaf pectinase powder was stored up to 16 months at ambient temperature without loss of enzyme activity, unlike commercial enzyme products.
This leaf-production platform is a novel technology for enzyme production with the elimination of fermentation, purification, concentration, formulation and cold chain processes.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Read the full report: https://www.reportlinker.com/p06151648/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001